세계의 호르몬 대체 요법 시장 : 규모, 점유율, 동향 분석(제품별, 투여 경로별, 질환 유형별, 지역별), 부문별 예측(2025-2033년)

Hormone Replacement Therapy Market Size, Share & Trends Analysis Report By Product, (HGH Replacement Therapy), By Route of Administration, By Disease Type, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,833,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,318,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,288,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

호르몬 대체 요법 시장 요약

세계의 호르몬 대체 요법 시장 규모는 2024년에 235억 8,000만 달러로, 2033년까지 394억 2,000만 달러에 이를 것으로 예측되며, 2025년부터 2033년까지 CAGR은 5.8%로 나타날 것으로 예상됩니다.

호르몬 대체 요법 산업은 특히 노인 인구 중 호르몬 장애의 유병률이 증가하고 있기 때문에 기세가 증가하고 있습니다.

홍조, 식은땀, 질 건조, 골다공증과 같은 폐경과 관련된 증상은 효과적인 치료법에 대한 수요를 부추깁니다. 예를 들어, 2024년 10월, StatPearls Publishing은 중등도에서 중증의 혈관 운동 증상의 관리에 HRT를 사용하였으며, 875명의 여성을 대상으로 한 Postmenopausal Estrogen/Progestin Interventions 시험에서는 에스트로겐 단독군(OR, 0.42, 95% CI, 0.28-0.62) 및 에스트로겐 + 프로게스틴 군(OR, 0.38, 95% CI, 0.25-0.58)은 위약에 비해 유의한 증상 경감이 인정되었다고 보고하고 있습니다. 이 연구는 증상 완화에서 HRT의 중요성을 강조하는 반면 만성 질환 예방에서 HRT의 제한된 역할을 밝혔습니다. 남성 성선 기능 저하증에 대한 인식이 증가함에 따라 평균 수명이 증가함에 따라 시장 채택이 더욱 확대되고 있습니다.

Oxford-Royal College of General Practitioners Research and Surveillance Centre의 연구는 465개 일반 클리닉에서 180만 건의 의료 기록을 분석하고 에스트로겐 기반 HRT를 받은 5,451명의 여성에서 COVID-19 감염률과 사망률이 78% 감소한 것으로 보고되었습니다. 갱년기 장애, 성선 기능 저하증, 성장 호르몬 결핍증 등의 질병에 대한 인식이 높아지고 환자층이 확대되고 있습니다. 제약 회사는 수요를 충족시키기 위해 혁신적인 치료법을 도입했습니다. 예를 들어, Ascendis Pharma A/S는 2022년 1월 소아성장 호르몬 분비 부전증에 대한 첫 주 1회 투여 치료제인 SKYTROFA의 유럽 위원회 승인을 취득하여 매일 주사에 비해 복약 어드밴스와 편리성이 향상되었습니다.

시장 성장은 호르몬 결핍증과 희귀질환에 대한 의식이 높아짐에 따라 더욱 향상되었습니다. 영국에 본사를 둔 Child Growth Foundation과 같은 조직은 환자, 간병인, 의료 제공업체에게 교육, 지도, 지원을 제공하고 HRT 채용을 촉진하고 있습니다. 이러한 기세에도 불구하고 일부 지역에서는 고액의 치료비가 여전히 장벽이 되고 있습니다. 주사용 HRT의 연간 비용은 보험 가입자의 경우 288-1,440달러, 보험 미가입자의 경우 480-4,800달러이며, 이는 이용 가능성을 제한하고 있습니다. 그럼에도 불구하고 환자의 의식 증가, 혁신적인 약물 전달 방법, 치료 용도의 확대는 호르몬 대체 요법 업계의 장기 성장을 유지할 것으로 예측됩니다.

목차

제1장 분석 방법 및 범위

제2장 주요 요약

제3장 호르몬 대체 요법 시장 : 변동 요인, 동향 및 범위

• 시장 연관 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 업계 분석 : Porter's Five Forces 분석
  • PESTEL 분석
  • 파이프라인 분석
  • 특허 만료 분석
  • 가격 분석

제4장 호르몬 대체 요법 시장 : 제품별 비즈니스 분석

• 시장 점유율 : 제품별(2024년 및 2033년)
• 제품별 대시보드
• 시장 규모 예측과 동향 분석 : 제품별(2021-2033년)
• 에스트로겐 및 프로게스테론 대체 요법
• HGH 대체 요법
• 갑상선 호르몬 대체 요법
• 테스토스테론 대체 요법
• 부갑상선 호르몬 대체 요법

제5장 호르몬 대체 요법 시장 : 투여 경로별 비즈니스 분석

• 시장 점유율 : 투여 경로별(2024년 및 2033년)
• 투여 경로별 대시보드
• 시장 규모 예측과 동향 분석 : 투여경로별(2021-2033년)
• 경구
• 비경구
• 경피
• 기타

제6장 호르몬 대체 요법 시장 : 질병 유형별 비즈니스 분석

• 시장 점유율: 질병 유형별(2024년 및 2033년)
• 질병 유형별 대시보드
• 시장 규모의 예측과 동향 분석 : 질병 유형별(2021-2033년)
• 폐경
• 갑상선 기능 저하증
• 남성 생식선 기능 저하증
• 성장 호르몬 결핍증
• 부갑상선 기능 저하증

제7장 호르몬 대체 요법 시장 : 지역별 추정 및 동향 분석

• 시장 점유율 분석 : 지역별(2024년 및 2033년)
• 지역별 시장 대시보드
• 시장 규모 예측과 동향 분석(2021-2033년)
• 북미
  • 국가별(2021-2033년)
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 참가 기업의 개요
• 기업의 시장 포지셔닝 분석
• 기업 분류
• 전략 매핑
• 기업 프로파일/상장 기업
  • Eli Lilly and Company
  • Bayer AG
  • Noven Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Viatris, Inc.
  • Novo Nordisk A/S
  • F. Hoffmann-La Roche Ltd.
  • ASCEND Therapeutics US, LLC.
  • AbbVie, Inc.

JHS

영문 목차

영문목차

Hormone Replacement Therapy Market Summary

The global hormone replacement therapy market size was estimated at USD 23.58 billion in 2024 and is projected to reach USD 39.42 billion by 2033, growing at a CAGR of 5.8% from 2025 to 2033. The hormone replacement therapy industry is gaining momentum due to the rising prevalence of hormonal disorders, especially among aging populations.

Menopause-related conditions such as hot flashes, night sweats, vaginal dryness, and osteoporosis are fueling demand for effective therapies. For instance, October 2024, StatPearls Publishing reported that HRT was used to manage moderate-to-severe vasomotor symptoms, with the Postmenopausal Estrogen/Progestin Interventions trial of 875 women showing significant symptom reduction in estrogen-alone (OR, 0.42; 95% CI, 0.28-0.62) and estrogen-plus-progestin groups (OR, 0.38; 95% CI, 0.25-0.58) compared to placebo. The study clarified HRT's limited role in chronic disease prevention while highlighting its importance in symptom relief. Growing awareness of male hypogonadism, coupled with rising life expectancy, further expands market adoption.

A study by the Oxford-Royal College of General Practitioners Research and Surveillance Centre, analyzing 1.8 million medical records from 465 general practices, reported that 5,451 women on estrogen-based HRT experienced a 78% reduction in COVID-19 infection and mortality rates. Rising awareness of conditions such as menopause, hypogonadism, and growth hormone deficiency is expanding the patient base. Pharmaceutical companies are introducing innovative therapies to meet demand. For example, in January 2022, Ascendis Pharma A/S received European Commission approval for SKYTROFA, the first once-weekly treatment for pediatric growth hormone deficiency, offering improved adherence and convenience compared to daily injections.

Market growth is further supported by increasing awareness of hormone deficiencies and rare disorders. Organizations like the UK-based Child Growth Foundation provide education, guidance, and support to patients, caregivers, and healthcare providers, enhancing adoption of HRT. Despite this momentum, high treatment costs remain a barrier in certain regions. Annual injectable HRT costs range from USD 288 to USD 1,440 for insured patients and USD 480 to USD 4,800 for uninsured individuals, limiting accessibility. Nevertheless, rising patient awareness, innovative drug delivery methods, and expanded therapeutic applications are expected to sustain long-term growth in the hormone replacement therapy industry.

Global Hormone Replacement Therapy Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hormone replacement therapy market report based on product, route of administration, disease type, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Estrogen & Progesterone Replacement Therapy
• HGH Replacement Therapy
• Thyroid Hormone Replacement Therapy
• Testosterone Replacement Therapy
• Parathyroid Hormone Replacement
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Oral
• Parenteral
• Transdermal
• Others
• Disease Type Outlook (Revenue, USD Million, 2021 - 2033)
• Menopause
• Hypothyroidism
• Male Hypogonadism
• Growth Hormone Deficiency
• Hypoparathyroidism
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Route of Administration
  • 1.2.3. Disease Type
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Hormone Replacement Therapy Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Hormone Replacement Therapy Market: Product Business Analysis

• 4.1. Product Market Share, 2024 & 2033
• 4.2. Product Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Estrogen & Progesterone Replacement Therapy
  • 4.4.1. Estrogen & Progesterone Replacement Therapy Market, 2021 - 2033 (USD Million)
• 4.5. HGH Replacement Therapy
  • 4.5.1. HGH Replacement Therapy Market, 2021 - 2033 (USD Million)
• 4.6. Thyroid Hormone Replacement Therapy
  • 4.6.1. Thyroid Hormone Replacement Therapy Market, 2021 - 2033 (USD Million)
• 4.7. Testosterone Replacement Therapy
  • 4.7.1. Testosterone Replacement Therapy Market, 2021 - 2033 (USD Million)
• 4.8. Parathyroid Hormone Replacement
  • 4.8.1. Parathyroid Hormone Replacement Market, 2021 - 2033 (USD Million)

Chapter 5. Hormone Replacement Therapy Market: Route of Administration Business Analysis

• 5.1. Route of Administration Market Share, 2024 & 2033
• 5.2. Route of Administration Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Route of administration, 2021 to 2033 (USD Million)
• 5.4. Oral
  • 5.4.1. Oral Market, 2021 - 2033 (USD Million)
• 5.5. Parenteral
  • 5.5.1. Parenteral Market, 2021 - 2033 (USD Million)
• 5.6. Transdermal
  • 5.6.1. Transdermal Market, 2021 - 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Hormone Replacement Therapy Market: Disease Type Business Analysis

• 6.1. Disease Type Market Share, 2024 & 2033
• 6.2. Disease Type Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Disease type, 2021 to 2033 (USD Million)
• 6.4. Menopause
  • 6.4.1. Menopause Market, 2021 - 2033 (USD Million)
• 6.5. Hypothyroidism
  • 6.5.1. Hypothyroidism Market, 2021 - 2033 (USD Million)
• 6.6. Male Hypogonadism
  • 6.6.1. Male Hypogonadism Market, 2021 - 2033 (USD Million)
• 6.7. Growth Hormone Deficiency
  • 6.7.1. Growth Hormone Deficiency Market, 2021 - 2033 (USD Million)
• 6.8. Hypoparathyroidism
  • 6.8.1. Hypoparathyroidism Market, 2021 - 2033 (USD Million)

Chapter 7. Hormone Replacement Therapy Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 7.4. North America
  • 7.4.1. North America Hormone Replacement Therapy Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Target Disease Prevalence
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Framework
    • 7.4.2.5. U.S. Hormone Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Framework
    • 7.4.3.5. Canada Hormone Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Framework
    • 7.4.4.5. Mexico Hormone Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Hormone Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Target Disease Prevalence
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Framework
    • 7.5.2.5. UK Hormone Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Framework
    • 7.5.3.5. Germany Hormone Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Target Disease Prevalence
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement Framework
    • 7.5.4.5. France Hormone Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Target Disease Prevalence
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Reimbursement Framework
    • 7.5.5.5. Italy Hormone Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Target Disease Prevalence
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Reimbursement Framework
    • 7.5.6.5. Spain Hormone Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Target Disease Prevalence
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Reimbursement Framework
    • 7.5.7.5. Denmark Hormone Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Target Disease Prevalence
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Reimbursement Framework
    • 7.5.8.5. Sweden Hormone Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Target Disease Prevalence
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Reimbursement Framework
    • 7.5.9.5. Norway Hormone Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Hormone Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Target Disease Prevalence
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Framework
    • 7.6.2.5. Japan Hormone Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Framework
    • 7.6.3.5. China Hormone Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Target Disease Prevalence
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Framework
    • 7.6.4.5. India Hormone Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Target Disease Prevalence
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Framework
    • 7.6.5.5. Australia Hormone Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Target Disease Prevalence
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement Framework
    • 7.6.6.5. South Korea Hormone Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Target Disease Prevalence
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement Framework
    • 7.6.7.5. Thailand Hormone Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Hormone Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Target Disease Prevalence
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement Framework
    • 7.7.2.5. Brazil Hormone Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Target Disease Prevalence
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement Framework
    • 7.7.3.5. Argentina Hormone Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Middle East and Africa
  • 7.8.1. Middle East and Africa Hormone Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Target Disease Prevalence
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement Framework
    • 7.8.2.5. South Africa Hormone Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Target Disease Prevalence
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement Framework
    • 7.8.3.5. Saudi Arabia Hormone Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Target Disease Prevalence
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Reimbursement Framework
    • 7.8.4.5. UAE Hormone Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Target Disease Prevalence
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Reimbursement Framework
    • 7.8.5.5. Kuwait Hormone Replacement Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Eli Lilly and Company
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Bayer AG
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Noven Pharmaceuticals, Inc.
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Pfizer Inc.
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Merck & Co., Inc.
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Viatris, Inc.
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Novo Nordisk A/S
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. F. Hoffmann-La Roche Ltd.
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. ASCEND Therapeutics US, LLC.
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. AbbVie, Inc.
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives

관련자료